Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis C Blood-Borne Infections Chronic Disease Communicable Diseases Digestive System Diseases Disease Attributes Flaviviridae Infections Hepatitis Hepatitis C, Chronic Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms RNA Virus Infections Virus Diseases

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Toranomon Hospital

Kawasaki, Takatsu-ku, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with genotype 1b chronic hepatitis C
Patients naive to the concomitant medications with interferon

Exclusion criteria

Patients diagnosed with decompensated cirrhosis
Patients diagnosed with positive HBs antigen in the test

Treatment and study plan

MP-424 (Telaprevir)

Drug

Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)

Other names: Telaprevir

Primary outcomes

Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration

Time frame: 24 Weeks After Completion of Drug Administration (dosing period is 24 Weeks) or drug withdrawal. The subjects were assessed at 24 weeks following the last dose of study drug.

Sponsors and collaborators

Lead sponsor

Tanabe Pharma Corporation

Industry

Collaborators

Vertex Pharmaceuticals Incorporated

Registry information

Official study title

Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2009
First posted: Feb 22, 2008
Registry last updated: Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed